Wednesday July 22, 2020 0 comments
BOULDER -- Biodesix, Inc. announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors.
Ms. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Mr. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.
“Jean and Hany both have exceptional strategic expertise, which will be invaluable for Biodesix as we move into a new phase of growth,” said Scott Hutton, Biodesix CEO.
“They both have proven track records demonstrating their ability to see the big picture and streamline financial and organizational operations. This experience will complement Biodesix’s existing capabilities, making us better equipped to provide the vital diagnostic tools for which we are known.”
Franchi currently serves as chief financial officer for Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies.
She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme, where she supported the company during its most rapid growth phase.
Franchi served as chief financial officer at numerous other public and private companies before joining Replimune Group in 2019. She earned a bachelor's degree in business administration from Hofstra University.
Massarany served as president and chief executive officer of GenMark Diagnostics, Inc. (NASDAQ: GNMK) from 2011 to 2020.
Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009, Mr. Massarany was responsible for various global leadership positions with Ventana.
He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics, working in Asia Pacific and the United States. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University, Australia and an MBA from Melbourne University, Australia.